Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 20 May 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Sargramostim for active Crohn's disease

Findings for the secondary end points of a study in this week's New England Journal of Medicine suggest that sargramostim therapy decreases disease severity and improves the quality of life in patients with active Crohn's.

News image

fiogf49gjkf04

Sargramostim, granulocyte–macrophage colony-stimulating factor, a hematopoietic growth factor, stimulates cells of the intestinal innate immune system.

Preliminary studies suggest sargramostim may have activity in Crohn's disease.

Dr Korzenik and colleagues evaluated this novel therapeutic approach by conducting a randomized, placebo-controlled trial.

The sargramostim group had significant improvements in quality of life
New England Journal of Medicine

Using a 2 to 1 ratio, the researchers randomly assigned 124 patients with moderate-to-severe active Crohn's disease to treatment and control groups.

The patients were randomized to receive either 6 µg of sargramostim per kilogram per day or placebo subcutaneously for 56 days.

The research team reported that antibiotics and aminosalicylates were allowed, whilst immunosuppressants and glucocorticoids were prohibited.

The primary end point was a clinical response, defined by a decrease from baseline of at least 70 points in the Crohn's Disease Activity Index on day 57.

The researchers included other end points of changes in disease severity and adverse events.

Endpoints relating to change in quality of life included a decrease from baseline of 100 points in the Crohn's Disease Activity Index score on day 57, and remission, defined by a index score of 150 points or less on day 57.

The researchers found no significant difference in the rate of the primary end point of a clinical response between the sargramostim and placebo groups.

However, the team noted significantly more patients in the sargramostim group than in the placebo group reached the secondary end points of a clinical response of a decrease and remission of the Crohn's Disease Activity Index.

The rates of either type of clinical response and of remission were significantly higher in the sargramostim group on day 29 of treatment and 30 days after treatment.

The researchers also observed that the sargramostim group had significant improvements in the quality of life.

The research team found that mild-to-moderate injection-site reactions and bone pain were more common in the sargramostim group.

In addition, the team noted that 3 patients in the sargramostim group had serious adverse events possibly or probably related to treatment.

Dr Korzenik's team concluded, “This study was negative for the primary end point.”

“However, findings for the secondary end points suggest that sargramostim therapy decreased disease severity and improved the quality of life in patients with active Crohn's disease.”

NEJM 2005: 352(21): 2193-2201
30 May 2005

Go to top of page Email this page Email this page to a colleague

 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
Hep B in the Grey Zone
 15 May 2018 
New therapies for CDI
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 11 May 2018 
Depressive symptoms in IBD youth
 10 May 2018 
Post‐operative complications in elderly IBD
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 09 May 2018 
Esophageal dilatation in clinical practice 
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
PPI use and cognitive decline
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Symptom assessment in cirrhotic ascites
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Chronic Hep B
 01 May 2018 
European guidelines on pancreatic cystic neoplasms
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
Age at IBD onset and extraintestinal complications
 30 April 2018 
Formula for preterm infants
 30 April 2018 
Primary antibiotic resistance and sequential therapy for H. pylori
 30 April 2018 
Patient-reported outcome measures in IBD trials
 27 April 2018 
Anxiety scale for chronic esophageal disease
 27 April 2018 
Disease activity in eosinophilic esophagitis
 27 April 2018 
Eastern and western practices for endoscopic resection of colorectal lesions
 26 April 2018 
Obesity and physical activity in diverticulosis
 26 April 2018 
Fecal incontinence and quality of life in IBD
 26 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Aspirin and pancreatic cancer
 25 April 2018 
Central mediators of irinotecan-induced steatohepatitis
 25 April 2018 
Neuroimaging in Hep C
 24 April 2018 
Scoring system identifies cancer risk in Barrett's
 24 April 2018 
Microbiome in athletes vs sedentary subjects
 24 April 2018 
PPI and risk of stroke
 23 April 2018 
Genome-wide study on HBV-related acute-on-chronic liver failure
 23 April 2018 
Antibody suitable for further clinical development to complement existing therapeutic strategies for HCV
 23 April 2018 
Sleep deprivation and NAFLD in the USA
 20 April 2018 
Two annexin A11 epitopes targeted by IgG1 and IgG4 autoantibodies were shared between patients with IAC/AIP and IgG4 antibodies blocked binding of IgG1 antibodies to the shared annexin A11 epitopes
 20 April 2018 
Adalimumab with azathioprine in Crohn's
 20 April 2018 
Worldwide H.pylori prevalence
 19 April 2018 
c-Myc expression and pancreatic cancer
 19 April 2018 
Olmesartan prescription in the USA

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us